Aprepitant (EMEND): the role of substance P in nausea and vomiting.
Aprepitant (EMEND) is the first commercially available drug from a new class of agents, the Substance P/neurokinin NK-1 receptor antagonists. Aprepitant is indicated for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with highly emetogenic chemotherapy in adults. Its ability to antagonize the effects of Substance P has lead to greater understanding of the pathophysiology of nausea and vomiting. Its broad range of activity against a wide variety of central and peripheral emetogenic stimuli make it potentially useful in non-chemotherapy related nausea and vomiting.
Prommer
Eric
E
UCLA School of Medicine, Division of Hematology/Oncology, Los Angeles, CA 90073, USA. eric.prommer@med.va.gov
D000818:Animals; D000932:Antiemetics / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects; D000077608:Aprepitant; D002945:Cisplatin / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects; D004347:Drug Interactions; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D009025:Morpholines / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D009325:Nausea / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D064729:Neurokinin-1 Receptor Antagonists; D018040:Receptors, Neurokinin-1 / Q000378:metabolism; D013373:Substance P / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014839:Vomiting / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*
D000932:Antiemetics; D000970:Antineoplastic Agents; D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists; D018040:Receptors, Neurokinin-1; D000077608:Aprepitant; D013373:Substance P; D003577:Cytochrome P-450 Enzyme System; D002945:Cisplatin